Fig. 1 · Structure

Documents & Downloads

Myricitrin (Myricitrine)

Cat. No. A10616 CAS 17912-87-7
Myricitrin is the 3-O-rhamnoside of myricetin. Myricitrin is used by several beetle species in their communication system.

In Stock

Publications for Myricitrin

1 publication citing this product

  1. Ayumi Yamamoto, .et al. , Nutrients, 2022, Mar 4;14(5):1078 PMID: 35268053

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PKCα
PKCε

Myricitrin (Myricitrine) Research Summary

This section summarizes 2 in vitro studies of Myricitrin (Myricitrine) from 2 published references.

Myricitrin (Myricitrine) In Vitro Studies

Myricitrin did not significantly increase BrdU incorporation in primary rat skeletal muscle satellite-cell cultures at 25 or 100 nM. Casuarinin and the HGF positive control increased incorporation in the same experiment. The lemon myrtle extract’s satellite-cell activation therefore cannot be assigned to myricitrin on these results. [1]

In C2C12 cultures exposed to 100 mM glucose for 48 h, myricitrin produced concentration-dependent redox-marker changes. SOD increased at 1 μM and MDA decreased at 3 μM relative to untreated high glucose. At 10 μM, SOD instead decreased further and MDA remained above the normal-glucose control. CAT increased at all three concentrations. The mixed response limits a general claim of antioxidant protection. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

No significant stimulation of rat satellite-cell BrdU incorporation

Cell-based study · Primary skeletal muscle satellite-cell cultures isolated from male Sprague-Dawley rats over 6 months old [1]

Myricitrin at 25 and 100 nM did not significantly promote BrdU incorporation relative to control medium. Casuarinin and the HGF positive control were active in the same comparison. This is a model- and concentration-specific negative finding; it does not establish general inactivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BrdU-positive satellite cells as a fraction of total satellite cells, expressed as fold change versus controlStatistical comparison with control No significant promotion at 25 or 100 nM; Results 3.3 reports all p > 0.71 for the four non-casuarinin compounds collectively. No myricitrin-specific exact p value or numerical fold change is supplied in the text.[1]

Literature-Reported Treatment Conditions

Treatment concentration
25 and 100 nM
Exposure duration
22 h sample incubation followed by a 2 h BrdU pulse
Method
Addition to 10% horse-serum DMEM; 10 μM BrdU pulse
Vehicle
Samples were dissolved in water or DMSO before dilution into medium; compound-specific choice and final DMSO percentage are not specified. Control was 10% horse-serum DMEM.
Reported limits
Purchased myricitrin catalog number, lot, purity and compound-specific stock solvent are not supplied in the relevant methods.
Methods and source locations

Compound reported in the paper: Myricitrin; Compound label in the paper: Myricitrin (Adooq Bioscience)

Reported myricitrin comparison only; extract and casuarinin activity must not be attributed to myricitrin or to a current Adooq lot.

Methods 2.2–2.5 and 2.10; Results 3.3; Figure 3a and caption

BrdU-positive satellite cells as a fraction of total satellite cells, expressed as fold change versus control: BrdU immunocytochemistry and microscopic cell counting; Figure 3 caption: mean ± SD, three independent cultures for each compound condition; control and HGF have nine independent cultures. One-way ANOVA with Dunnett’s multiple comparison test. — Methods 2.2–2.5 and 2.10; Results 3.3; Figure 3a and caption

Concentration-dependent redox-marker responses in high-glucose C2C12 cultures

Cell-based study · Mouse skeletal muscle C2C12 cultures exposed to 100 mM D-glucose; 5 mM D-glucose control [2]

Over 48 h, the reported marker response depended on concentration: 1 μM increased SOD and 3 μM lowered MDA, whereas 10 μM further decreased SOD relative to untreated high glucose. CAT rose at all tested concentrations. These are biochemical readouts from a cellular experiment, not proof of a direct molecular target or uniform cytoprotection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Malondialdehyde (MDA)Reported direction and statistical comparison At 3 μM, lower than untreated 100 mM glucose group (p < 0.05). At 10 μM, remained higher than the 5 mM glucose control (p < 0.05); no significant decrease versus untreated high glucose is identified for 10 μM in the results.[2]
Superoxide dismutase (SOD)Reported direction and statistical comparison At 1 μM, increased versus untreated high glucose (p < 0.05); at 10 μM, decreased further versus untreated high glucose (p < 0.01). SOD at 3 and 10 μM remained below the 5 mM glucose control (p < 0.01 and p < 0.001, respectively).[2]
Catalase (CAT) and total antioxidant capacity (TAC)Reported direction and statistical comparison CAT increased at 1, 3 and 10 μM versus untreated high glucose (p < 0.01). TAC decreased at 3 and 10 μM versus untreated high glucose (p < 0.001); TAC remained above the 5 mM glucose control in every high-glucose group (p < 0.001).[2]

Literature-Reported Treatment Conditions

Treatment concentration
Myricitrin 1, 3 or 10 μM with D-glucose 100 mM; untreated high-glucose comparator and 5 mM glucose control
Exposure duration
48 h concurrent exposure
Method
Addition to C2C12 culture medium
Co-treatment
Concurrent high-glucose challenge; no second therapeutic compound
Reported limits
Myricitrin stock solvent/final vehicle, lot, purity and an osmolarity-matched control are not specified in the reviewed methods. Differentiation conditions are not described, despite use of both myoblast and myotube terminology. The independence level of reported n = 3 is not explained.
Methods and source locations

Compound reported in the paper: Myricitrin; Compound label in the paper: Myricitrin (AvaChem Scientific)

Reported C2C12 high-glucose marker comparisons only; no inference about direct PKC/NO inhibition, clinical efficacy, or current Adooq lot performance.

Methods: Materials, Cell culture, Experimental design, Lipid peroxidation and antioxidants enzyme measurements, Statistical assessment; Results: antioxidant defense; Figure 1a–d and caption

Malondialdehyde (MDA): Commercial assays on cell-homogenate supernatants (MDA, CAT and TAC: Zellbio; SOD: Randox). Mean ± SEM; reported n = 3 per group. One-way ANOVA followed by least significant difference tests. Absolute concentrations are not reconstructed from the plotted bars. — Methods: Materials, Cell culture, Experimental design, Lipid peroxidation and antioxidants enzyme measurements, Statistical assessment; Results: antioxidant defense; Figure 1a–d and caption

Superoxide dismutase (SOD): Commercial assays on cell-homogenate supernatants (MDA, CAT and TAC: Zellbio; SOD: Randox). Mean ± SEM; reported n = 3 per group. One-way ANOVA followed by least significant difference tests. Absolute concentrations are not reconstructed from the plotted bars. — Methods: Materials, Cell culture, Experimental design, Lipid peroxidation and antioxidants enzyme measurements, Statistical assessment; Results: antioxidant defense; Figure 1a–d and caption

Catalase (CAT) and total antioxidant capacity (TAC): Commercial assays on cell-homogenate supernatants (MDA, CAT and TAC: Zellbio; SOD: Randox). Mean ± SEM; reported n = 3 per group. One-way ANOVA followed by least significant difference tests. Absolute concentrations are not reconstructed from the plotted bars. — Methods: Materials, Cell culture, Experimental design, Lipid peroxidation and antioxidants enzyme measurements, Statistical assessment; Results: antioxidant defense; Figure 1a–d and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 17912-87-7
Formula C21H20O12
Molecular Weight 464.4
Synonyms Myricitrine; Myricitroside; Myricetol 3-rhamnoside; Myricetin 3-O-rhamnoside
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C(=C4)O)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 91 mg/mL (195.95 mM)
Water Insoluble
Ethanol 1 mg/mL (2.15 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Myricitrin (Myricitrine) Research References

  1. [1] Yamamoto A, Honda S, Ogura M, et al. Lemon Myrtle (Backhousia citriodora) Extract and Its Active Compound, Casuarinin, Activate Skeletal Muscle Satellite Cells In Vitro and In Vivo Nutrients (2022). PMID: 35268053 DOI: 10.3390/nu14051078 Source material
  2. [2] Ahangarpour A, Oroojan AA, Khorsandi L, et al. Antioxidant effect of myricitrin on hyperglycemia-induced oxidative stress in C2C12 cell Cell stress & chaperones (2018). PMID: 29516429 DOI: 10.1007/s12192-018-0888-z Source material

Publications

1 publication citing this product

  1. Ayumi Yamamoto, .et al. , Nutrients, 2022, Mar 4;14(5):1078 PMID: 35268053

Added to your cart

View Cart Checkout
Loading...